You can buy or sell NexImmune and other stocks, options, and ETFs commission-free!
NexImmune, Inc. engages in the development of novel approach to immunotheraphy designed to create therapies with curative potential for patients with cancer and other life threatening immune-mediated diseases. Its product candidates are NEXI-001 in acute myeloid leukemia, or AML, and NEXI-002 in multiple myeloma, or MM.
52 Week High
52 Week Low
— per share
Expected Aug 16, After Hours